Affinage

GPR37L1

G-protein coupled receptor 37-like 1 · UniProt O60883

Length
481 aa
Mass
52.8 kDa
Annotated
2026-06-10
30 papers in source corpus 17 papers cited in narrative 17 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

GPR37L1 is an astrocyte-enriched family A orphan G-protein-coupled receptor that governs glial maturation, neuroprotection, and neural pathway signaling across cerebellar development, the spinal cord, dorsal root ganglia, and central cardiovascular control (PMID:24062445, PMID:37029775, PMID:39952243). It is activated by the prosaposin-derived peptide prosaptide/TX14(A), which drives receptor endocytosis, ERK phosphorylation, and inhibition of cAMP in a pertussis toxin-sensitive (Gi-coupled) manner and confers neuroprotection against oxidative stress in astrocytes (PMID:23690594, PMID:30260505); functional coupling requires a native glial context, as heterologous HEK293 expression yields non-responsive receptor (PMID:30260505). Receptor activity is set by its N-terminus, which is proteolytically cleaved by ADAM/matrix metalloproteases between residues 105–122 (the larger surface species being N-glycosylated at Asn105), with the cleaved species predominating in vivo and an intact N-terminus required for constitutive Gαs coupling (PMID:33203955). A second ligand, the pro-resolving lipid mediator maresin 1, couples GPR37L1 to potassium channel (KCNJ10/KCNJ3) surface expression in satellite glial cells and to glutamate transporter GLT-1 activity in spinal dorsal horn astrocytes, driving resolution of neuropathic pain (PMID:38530364, PMID:39952243). In the cerebellum GPR37L1 localizes to Bergmann glia primary cilia and physically interacts with the Hedgehog receptor Patched 1 to restrain Ptch1 internalization, Smoothened ciliary trafficking, and Shh mitogenic signaling, with loss-of-function promoting precocious glial maturation and modulating medulloblastoma pathogenesis (PMID:24062445, PMID:33350496, PMID:30452905). The receptor additionally interacts with MLC1/GlialCAM in an osmolarity- and potassium-sensitive manner, with dopamine D2 receptors, and forms homo- and heterodimers with GPR37 (PMID:34100078, PMID:30423289, PMID:34822195). Loss of GPR37L1 impairs cortical astrocyte maturation and morphology, increases seizure susceptibility, and disrupts central autonomic cardiovascular control in a sex-specific manner (PMID:37029775, PMID:28688853, PMID:33633567).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2013 High

    Established the first ligand and signaling output for an orphan receptor, showing GPR37L1 is engaged by the prosaposin fragment prosaptide and signals via Gi to suppress cAMP and activate ERK with a neuroprotective consequence.

    Evidence Transfected-cell signaling assays (ERK, 35S-GTPγS, cAMP), endocytosis, and siRNA knockdown with oxidative-stress protection readout

    PMID:23690594

    Open questions at the time
    • Direct physical ligand-receptor binding not demonstrated
    • Endogenous physiological role of the Gi pathway not yet addressed in vivo
  2. 2013 High

    Placed GPR37L1 in a developmental signaling pathway by localizing it to Bergmann glia primary cilia and demonstrating a physical interaction with Patched 1 that modulates Shh-dependent cerebellar maturation.

    Evidence Gpr37l1 knockout mouse phenotyping, co-immunoprecipitation/colocalization with Ptch1, ciliary localization assays

    PMID:24062445

    Open questions at the time
    • Molecular mechanism by which GPR37L1 acts on Ptch1 not resolved at this stage
    • Whether ligand binding regulates the Ptch1 interaction unknown
  3. 2016 Low

    Proposed that GPR37L1 is constitutively Gαs-coupled and that its activity is switched off by ADAM-mediated N-terminal cleavage; this paper was later retracted but seeded the cleavage-regulation model.

    Evidence cAMP assays in transfected cells and cerebellar slices, ADAM inhibitor pharmacology, N-terminus deletion mutants (retracted)

    PMID:27072655

    Open questions at the time
    • Paper retracted; conclusions require independent confirmation
    • Apparent contradiction with Gi-coupled signaling reported elsewhere
  4. 2018 Medium

    Confirmed that prosaptide/TX14(A) neuroprotection operates through Gi and the cAMP-PKA axis in native astrocytes and demonstrated a strict cell-context requirement absent in HEK293 cells.

    Evidence Primary astrocyte cultures, pertussis toxin and PKA inhibitors, neuronal oxidative-stress protection, HEK293 vs astrocyte comparison

    PMID:30260505

    Open questions at the time
    • Identity of the astrocyte-specific cofactor enabling signaling unknown
    • Single lab
  5. 2018 Medium

    Extended the GPR37L1 interactome and dimerization repertoire by detecting interaction with the short D2 receptor isoform in live cells.

    Evidence Fluorescence cross-correlation spectroscopy in live N2a cells

    PMID:30423289

    Open questions at the time
    • Functional consequence of the GPR37L1–D2R interaction not defined
    • Single method, single lab
  6. 2018 Medium

    Revealed a sex-specific central role in cardiovascular regulation, with GPR37L1 loss raising blood pressure in females and worsening angiotensin II-induced hypertrophy in males despite undetectable cardiac/renal expression.

    Evidence Knockout mice, radiotelemetric blood pressure, angiotensin II challenge, tissue immunoblotting, β-gal reporter

    PMID:29625592

    Open questions at the time
    • Central neural circuit and downstream effectors unidentified
    • Partially contradicted by later replication
  7. 2020 High

    Defined the molecular basis of N-terminal regulation, mapping ADAM/MMP cleavage to residues 105–122 and N-glycosylation to Asn105, and confirming intact N-terminus is required for constitutive Gαs coupling using an independent yeast reconstitution system.

    Evidence HEK293/U87 expression, ADAM/MMP inhibitors, serial truncation mutants, yeast G-protein chimera assay, cerebellar tissue immunoblot

    PMID:33203955

    Open questions at the time
    • Identity of the specific protease(s) in vivo not pinned down
    • Relationship between Gαs constitutive activity and ligand-evoked Gi signaling unresolved
  8. 2020 Medium

    Mechanistically linked GPR37L1 to Hedgehog signaling control by showing its loss increases Ptch1 expression/internalization, cholesterol, ciliary Smo, and active Shh in Bergmann glia.

    Evidence Primary Gpr37l1-/- cerebellar astrocyte cultures, immunofluorescence, proliferation, cholesterol assays, prosaptide treatment

    PMID:33350496

    Open questions at the time
    • Direct mechanism of Ptch1 trafficking control not resolved
    • Single lab
  9. 2021 Medium

    Added MLC1/GlialCAM as direct, environmentally regulated GPR37L1 partners, connecting the receptor to glial ion/osmotic homeostasis machinery.

    Evidence GlialCAM interactome proteomics with Co-IP validation, Gpr37l1-/- immunohistochemistry, osmolarity/K+ challenge

    PMID:34100078

    Open questions at the time
    • Functional output of MLC protein upregulation in knockout not defined
    • Single lab
  10. 2021 Medium

    Showed GPR37L1 forms homo- and heterodimers with GPR37 while remaining properly trafficked, distinguishing it from aggregation-prone GPR37.

    Evidence FCCS, FRET, and FLIM in live N2a cells

    PMID:34822195

    Open questions at the time
    • Signaling consequence of GPR37L1–GPR37 heterodimers untested
    • Single lab
  11. 2024 High

    Identified maresin 1 as a GPR37L1 ligand in satellite glial cells and established a peripheral mechanism in which the receptor enhances Kir4.1/Kir3.1 surface expression to resolve neuropathic pain.

    Evidence Gpr37l1-/- and overexpression mice, electrophysiology, surface biotinylation, MaR1 binding assays, neuropathic pain behavior in mouse and human DRG

    PMID:38530364

    Open questions at the time
    • G-protein/effector coupling driving channel surface delivery not detailed
    • Relationship between MaR1 and prosaptide ligand activity unresolved
  12. 2024 Medium

    Functionally characterized rare GPR37L1 variants and linked the receptor to acute cholesterol regulation via the MAPK pathway downstream of prosaptide.

    Evidence Signaling assays in SK-N-MC cells (cAMP, MAPK), cholesterol quantification, KO cell line, variant expression constructs

    PMID:38569927

    Open questions at the time
    • Disease relevance of variant signaling deficits not established
    • Single lab
  13. 2025 High

    Demonstrated a central spinal astrocyte mechanism in which MaR1-activated GPR37L1 boosts GLT-1 activity and suppresses excitatory transmission, with selective astrocytic overexpression rescuing neuropathic pain and astrogliosis.

    Evidence Gpr37l1-/- mice, AAV astrocyte-specific knockdown/overexpression, GLT-1 assay, spinal EPSC electrophysiology, nerve injury pain model

    PMID:39952243

    Open questions at the time
    • Signaling cascade coupling GPR37L1 to GLT-1 not delineated
    • Endogenous source of MaR1 in spinal cord undefined
  14. 2017 Medium

    Linked GPR37L1 to seizure threshold control and showed genetic interaction with GPR37, with double knockout exacerbating seizure vulnerability.

    Evidence Single and double Gpr37l1/Gpr37 knockout mice seizure assays; K349N variant in transfected cells

    PMID:28688853

    Open questions at the time
    • Molecular mechanism of seizure protection unknown
    • K349N variant showed no detectable signaling defect
  15. 2020 Medium

    Defined the autonomic basis of the cardiovascular phenotype, implicating GPR37L1 in maintaining sympathetic vasomotor tone and, in females, cardiac vagal drive.

    Evidence Radiotelemetry, power spectral analysis, ganglionic blockade (pentolinium), stress tests in Gpr37l1-/- mice

    PMID:33633567

    Open questions at the time
    • Specific brainstem circuits and effectors not identified
    • Single lab
  16. 2023 Medium

    Established GPR37L1 as a regulator of astrocyte maturation, with its loss reducing mature gene expression, morphological complexity, and proper cortical tiling.

    Evidence RNA-seq of immunopanned P7 cortical astrocytes and morphological immunohistochemistry in Gpr37l1-/- mice

    PMID:37029775

    Open questions at the time
    • Signaling pathway driving maturation defect not identified
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How GPR37L1 reconciles constitutive Gαs activity, ligand-evoked Gi/cAMP-PKA signaling, and lipid (MaR1) versus peptide (prosaptide) ligands into a unified signaling logic, and how this is decoded differently across astrocyte subtypes, remains unresolved.
  • No structure of GPR37L1 with any ligand
  • Endogenous ligand sources in each tissue context undefined
  • Mechanistic chain from receptor to channel/transporter surface delivery not reconstituted

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0098772 molecular function regulator activity 3 GO:0048018 receptor ligand activity 2
Localization
GO:0005886 plasma membrane 2 GO:0005929 cilium 2
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-112316 Neuronal System 3 R-HSA-1266738 Developmental Biology 3
Partners
DRD2GPR37HEPACAMKCNJ10KCNJ3MLC1PTCH1

Evidence

Reading pass · 17 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 GPR37L1 is activated by prosaptide (active fragment of prosaposin), which promotes receptor endocytosis, stimulates ERK phosphorylation in a pertussis toxin-sensitive manner, stimulates 35S-GTPγS binding, and inhibits forskolin-stimulated cAMP production, indicating Gi-coupled signaling. Transfected cell signaling assays (ERK phosphorylation, 35S-GTPγS binding, cAMP measurement), endocytosis assays, siRNA knockdown with oxidative stress protection readout Proceedings of the National Academy of Sciences of the United States of America High 23690594
2013 GPR37L1 is localized to primary cilium membranes of Bergmann glia astrocytes in the cerebellum and physically interacts and colocalizes with the Sonic Hedgehog primary receptor Patched 1 (Ptch1); Gpr37l1 knockout results in premature downregulation of granule neuron precursor proliferation and precocious Bergmann glia and Purkinje neuron maturation, indicating GPR37L1 participates in postnatal cerebellar development by modulating the Shh pathway. Gpr37l1 knockout mice phenotypic analysis, colocalization/co-immunoprecipitation assays with Ptch1, primary cilium localization by specific assays Proceedings of the National Academy of Sciences of the United States of America High 24062445
2016 GPR37L1 is constitutively active and couples to Gαs when heterologously expressed; the N-terminus is necessary for this constitutive activity; ADAM metalloprotease-mediated cleavage of the N-terminus renders the receptor inactive; the cleaved, inactive form predominates in rodent cerebellum. NOTE: This paper was retracted. cAMP accumulation assays in transfected cells and cerebellar slice preparations from wild-type vs. GPR37L1-null mice, ADAM inhibitor pharmacology, N-terminus deletion mutant analysis Science signaling Low 27072655
2018 GPR37L1 mediates neuroprotective effects of TX14(A) (prosaptide/Saposin C fragment) in astrocytes, at least partially through Gi proteins and the cAMP-PKA axis, protecting neurons from oxidative stress; heterologous expression in HEK293 cells yields non-functional receptors that do not respond to TX14(A), suggesting a cell-context requirement. Primary astrocyte cultures, oxidative stress protection assay, pharmacological inhibition of Gi proteins (pertussis toxin), cAMP-PKA pathway inhibitors, comparison of HEK293 vs. native astrocyte expression systems Glia Medium 30260505
2018 GPR37L1 deletion causes female-specific increase in systolic, diastolic, and mean arterial blood pressure, while male GPR37L1-null mice develop exacerbated left ventricular hypertrophy upon angiotensin II challenge. GPR37L1 protein is abundant in the brain but undetectable in heart and kidney, indicating cardiovascular regulation occurs centrally. GPR37L1 knockout mice (C57BL/6J background), radiotelemetric blood pressure measurement, angiotensin II infusion challenge, immunoblotting of tissue expression, β-galactosidase reporter immunohistochemistry Biology of sex differences Medium 29625592
2018 GPR37L1 interacts with the short isoform of dopamine D2 receptor (D2R) in live cells, as detected by fluorescence cross-correlation spectroscopy (FCCS); this interaction was not modulated by 4-PBA or pramipexole treatment (unlike GPR37–D2R interaction). Fluorescence cross-correlation spectroscopy (FCCS) in live N2a cells Neuropharmacology Medium 30423289
2020 GPR37L1 N-terminus is proteolytically cleaved by matrix metalloproteases/ADAMs at a site between residues 105–122; the larger cell-surface species is N-glycosylated at Asn105; wild-type GPR37L1 (but not the Δ122 truncation mutant) constitutively couples to Gαs (and Gα16) chimeras in yeast; the cleaved, inactive species predominates in vivo and in cerebellar slice preparations. Heterologous expression in HEK293 and U87 cells, ADAM/MMP pharmacological inhibitors, serial N-terminal truncation mutants, yeast G-protein chimera signaling assay, immunoblotting of rodent cerebellum and organotypic slice preparations Scientific reports High 33203955
2020 In Bergmann glia primary cultures, Gpr37l1 loss-of-function increases cell proliferation, Ptch1 protein expression and internalization, intracellular cholesterol content, ciliary localization of Smoothened (Smo), and active Shh production, indicating GPR37L1–Ptch1 interactions regulate Ptch1 internalization/trafficking and downstream Shh mitogenic signaling. Primary cerebellar astrocyte cultures from wild-type and Gpr37l1-/- pups, immunofluorescence, proliferation assays, cholesterol measurement, prosaptide ligand treatment of wild-type cells Journal of neuroscience research Medium 33350496
2021 GPR37L1 directly interacts with MLC proteins (MLC1 and GlialCAM) in brain astrocytes; Gpr37l1 inactivation in mice upregulates MLC proteins without altering their localization; the interaction is dynamically regulated by changes in osmolarity or potassium concentration. GlialCAM interactome proteomics, co-immunoprecipitation validation, immunohistochemistry in Gpr37l1-/- mice, osmolarity/K+ challenge assays Human molecular genetics Medium 34100078
2021 GPR37L1 and GPR37 form homo- and heterodimers in live N2a cells; GPR37L1 does not aggregate in the cytoplasm (unlike GPR37 which forms cytoplasmic multimers reversible by Parkin overexpression). Fluorescence Cross-Correlation Spectroscopy (FCCS), Förster Resonance Energy Transfer (FRET), and Fluorescence Lifetime Imaging Microscopy (FLIM) in live N2a cells FASEB journal Medium 34822195
2024 GPR37L1 in satellite glial cells (SGCs) of dorsal root ganglia serves as a receptor for the pro-resolving lipid mediator maresin 1 (MaR1); upon activation, GPR37L1 enhances surface expression and function of potassium channels KCNJ10 (Kir4.1) and KCNJ3 (Kir3.1) in SGCs, increasing potassium influx; GPR37L1 loss impairs resolution of neuropathic pain while overexpression reverses it. Transgenic Gpr37l1-/- and overexpression mice, electrophysiology (potassium channel function), surface biotinylation (channel surface expression), GPR37L1 ligand binding assays with MaR1, neuropathic pain behavioral assays (PTX/STZ models) The Journal of clinical investigation High 38530364
2025 GPR37L1 activation by maresin 1 (MaR1) in spinal cord dorsal horn astrocytes increases glutamate transporter 1 (GLT-1) activity and reduces spinal EPSCs; Gpr37l1 knockdown in SDH astrocytes induces astrogliosis and pain hypersensitivity; Gpr37l1-/- mice fail to recover from neuropathic pain; selective Gpr37l1 overexpression in SDH astrocytes reverses neuropathic pain and astrogliosis after nerve injury. Gpr37l1-/- mice, AAV-mediated Gpr37l1 knockdown/overexpression in spinal cord astrocytes, GLT-1 functional assay, spinal EPSC electrophysiology, nerve injury neuropathic pain behavioral model Neuron High 39952243
2024 Rare GPR37L1 variants exhibit varying abilities to reduce cAMP levels, activate MAPK/ERK signaling, and upregulate receptor expression in response to prosaptide TX14(A); GPR37L1 knockout or expression of certain rare variants alters cellular cholesterol levels, which are also acutely regulated by TX14(A) via the MAPK pathway. Functional signaling assays in SK-N-MC cells (cAMP, MAPK), cholesterol quantification, GPR37L1 KO cell line, rare variant expression constructs The Journal of neuroscience Medium 38569927
2017 Complete loss of Gpr37l1 function in mice results in increased seizure susceptibility; combined deletion of Gpr37l1 and Gpr37 results in an even more dramatic increase in seizure vulnerability, indicating additive/epistatic interaction between the two receptors in seizure threshold control. The K349N human variant did not grossly alter receptor expression, surface trafficking, or constitutive signaling in transfected cells. Gpr37l1-/- and Gpr37-/- single and double knockout mice, seizure susceptibility assays; transfected cell expression and signaling assays for K349N variant Neurobiology of disease Medium 28688853
2020 GPR37L1-null mice of both sexes exhibit attenuated depressor responses to ganglionic blockade with pentolinium, indicating GPR37L1 is involved in maintaining sympathetic vasomotor tone; female GPR37L1-/- mice show reduced cardiac vagal drive (reduced heart rate spectral power 0.5–3 Hz) and attenuated cardiovascular reactivity to aversive environmental stimuli. Radiotelemetric blood pressure and heart rate measurement, power spectral analysis, pharmacological ganglionic blockade (pentolinium), behavioral stress tests in Gpr37l1-/- mice Frontiers in pharmacology Medium 33633567
2018 Genetic ablation of Gpr37l1 in Ptch1+/- mice delays medulloblastoma tumor onset and decreases incidence of aggressive tumor types; Gpr37l1-/-;Ptch1+/- pups show reduced granule cell precursor proliferation, thinner EGL, and precocious elevated Wnt3 expression compared to Ptch1+/- single mutants, indicating GPR37L1 modulates Shh-Ptch1-Smo mitogenic signaling in medulloblastoma pathogenesis. Double-mutant mouse model (Gpr37l1-/-;Ptch1+/-), natural history tumor analysis, histology of EGL, immunostaining for Wnt3 expression Experimental neurology Medium 30452905
2023 Loss of GPR37L1 in mice causes cortical astrocytes to express lower levels of mature astrocytic genes, exhibit shorter total process length, reduced morphological complexity, and increased spacing between astrocytes in the cortex, establishing GPR37L1 as a regulator of astrocyte maturation and morphological organization during development. RNA-seq of immunopanned cortical astrocytes from P7 Gpr37l1-/- vs. WT mice, immunohistochemistry of astrocyte morphology in cortex Glia Medium 37029775

Source papers

Stage 0 corpus · 30 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin. Proceedings of the National Academy of Sciences of the United States of America 194 23690594
2018 Glio- and neuro-protection by prosaposin is mediated by orphan G-protein coupled receptors GPR37L1 and GPR37. Glia 76 30260505
2013 Precocious cerebellum development and improved motor functions in mice lacking the astrocyte cilium-, patched 1-associated Gpr37l1 receptor. Proceedings of the National Academy of Sciences of the United States of America 53 24062445
2015 Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1. Frontiers in pharmacology 42 26635605
2017 GPR37L1 modulates seizure susceptibility: Evidence from mouse studies and analyses of a human GPR37L1 variant. Neurobiology of disease 37 28688853
2024 Satellite glial GPR37L1 and its ligand maresin 1 regulate potassium channel signaling and pain homeostasis. The Journal of clinical investigation 32 38530364
2016 RETRACTED: Metalloprotease cleavage of the N terminus of the orphan G protein-coupled receptor GPR37L1 reduces its constitutive activity. Science signaling 28 27072655
2025 GPR37L1 identifies spinal cord astrocytes and protects neuropathic pain after nerve injury. Neuron 26 39952243
2021 Identification of the GlialCAM interactome: the G protein-coupled receptors GPRC5B and GPR37L1 modulate megalencephalic leukoencephalopathy proteins. Human molecular genetics 23 34100078
2018 GPR37 and GPR37L1 differently interact with dopamine 2 receptors in live cells. Neuropharmacology 19 30423289
2020 Prosaposin and its receptors GRP37 and GPR37L1 show increased immunoreactivity in the facial nucleus following facial nerve transection. PloS one 15 33259479
2020 Gpr37l1/prosaposin receptor regulates Ptch1 trafficking, Shh production, and cell proliferation in cerebellar primary astrocytes. Journal of neuroscience research 14 33350496
2018 Genetic ablation of Gpr37l1 delays tumor occurrence in Ptch1+/- mouse models of medulloblastoma. Experimental neurology 14 30452905
2021 The expression of prosaposin and its receptors, GRP37 and GPR37L1, are increased in the developing dorsal root ganglion. PloS one 12 34379697
2021 Cytosolic GPR37, but not GPR37L1, multimerization and its reversal by Parkin: A live cell imaging study. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 11 34822195
2020 The N-terminus of GPR37L1 is proteolytically processed by matrix metalloproteases. Scientific reports 11 33203955
2018 Orphan receptor GPR37L1 contributes to the sexual dimorphism of central cardiovascular control. Biology of sex differences 11 29625592
2024 Genetically modified E. Coli secreting melanin (E.melanin) activates the astrocytic PSAP-GPR37L1 pathway and mitigates the pathogenesis of Parkinson's disease. Journal of nanobiotechnology 9 39523310
2023 GPR37L1 controls maturation and organization of cortical astrocytes during development. Glia 9 37029775
2021 Deletion of Orphan G Protein-Coupled Receptor GPR37L1 in Mice Alters Cardiovascular Homeostasis in a Sex-Specific Manner. Frontiers in pharmacology 9 33633567
2023 Expression patterns of prosaposin and its receptors, G protein-coupled receptor (GPR) 37 and GPR37L1, in the mouse olfactory organ. Tissue & cell 6 37075680
2021 Involvement of GPR37L1 in murine blood pressure regulation and human cardiac disease pathophysiology. American journal of physiology. Heart and circulatory physiology 6 34533400
2024 Rare GPR37L1 Variants Reveal Potential Association between GPR37L1 and Disorders of Anxiety and Migraine. The Journal of neuroscience : the official journal of the Society for Neuroscience 5 38569927
2023 Expression patterns of prosaposin and its receptors, G protein-coupled receptor (GPR) 37 and GPR37L1 mRNAs, in the chick inner ear. Cell and tissue research 5 36750499
2022 Mouse Mutants of Gpr37 and Gpr37l1 Receptor Genes: Disease Modeling Applications. International journal of molecular sciences 5 35457105
2020 Expression of the G protein-coupled receptor (GPR) 37 and GPR37L1 in the mouse digestive system. The Journal of veterinary medical science 5 33208571
2023 Satellite glial GPR37L1 regulates maresin and potassium channel signaling for pain control. bioRxiv : the preprint server for biology 3 38106084
2025 Astrocytic GPR37L1: A new guardian against the onset and chronicity of neuropathic pain. Neuron 1 40245840
2023 Rare GPR37L1 variants reveal potential roles in anxiety and migraine disorders. bioRxiv : the preprint server for biology 1 37461723
2022 Metabolic Profiling of Mice with Deletion of the Orphan G Protein-Coupled Receptor, GPR37L1. Cells 1 35681509

Missed literature

Know a paper Affinage missed for GPR37L1? Flag it for the maintainers and the community.

No submissions yet.